

## Achillion Pharmaceuticals Raised \$35 Million Series C-2 Financing (5/12/2006)

### Transaction Category

Venture Financing

### Company Information

Achillion Pharmaceuticals Inc

### Summary

On November 17, 2005, March 22, 2006 and May 12, 2006 Achillion Pharmaceuticals, Inc. has sold 23,425,462 shares of Series C-2 Convertible preferred stock to a group of 35 investors at \$1.50 per share. The investors consisted of SGC Partners I LLC, Stelios Papadopoulos, Bear Stearns Health Innoventures, L.P. Schroder Ventures International Life Sciences, Connecticut Innovations, Incorporated, Advent Partners HLS II Limited Partnership, Advent Partners Limited Partnership, Atlas Ventures, Scheer Investment Holdings III, L.L.C., Barbara Piette, PGE Investments 2002, LLC, KBL Healthcare, L.P., Gilead Sciences, Inc., International Biotechnology Private Ltd., Pound Capital Corporation, Capital Ventures International, Christopher White, Peter Reikes, David Malcolm and Kim Fennebresque.

### TRANSACTION DETAILS

Round Date	5/12/2006
Stage Type	Series C
Security Type	Preferred Stock
Investment Amount (In Million \$)	Equity: 35.14
No. of Shares	23,425,462
Per Share Value (In \$)	1.5

### INVESTORS

Firm Name	Fund Name	No. of Shares
Advent International Corp	Advent Partners LP	16,294
Advent International Corp	Advent Partners HLS II Limited Partnership	39,743
Advent International Corp	Advent Healthcare and Life Sciences II Limited Partnership	1,791,624
Advent International Corp	Advent Healthcare and Life Sciences II Beteiligung GMBH & Co. KG	139,498
Atlas Ventures	Atlas Venture Parallel Fund V-A, C.V	50,927
Atlas Ventures	Atlas Venture Fund V	3,059,559
Atlas Ventures	Atlas Venture Parallel Fund V-A C.V	760,092
Bear Stearns Health Innoventures(BSHI)	Bear Stearns Health Innoventures LP	257,888
Bear Stearns Health Innoventures(BSHI)	Bear Stearns Health Innoventures Employee Fund,	167,286
Bear Stearns Health Innoventures(BSHI)	BX, L.P	1,024,777

Bear Stearns Health Innoventures(BSHI)	Bear Stearns Health Innoventures Offshore	212,154
Bear Stearns Health Innoventures(BSHI)	BSHI Members, L.L.C	119,860
Capital Ventures International	--	--
Christopher A. White	--	16,666
Connecticut Innovations Inc	--	531,295
David Malcolm	--	--
Gilead Sciences Inc	--	--
KBL Healthcare Ventures	KBL Healthcare, L.P	--
KBL Healthcare Ventures	KBL Partnership, L.P	--
Kim Fennebresque	--	--
Peter Reikes	--	--
Pound Capital Ltd.	--	--
SV Life Sciences (formerly Schroder Ventures Life Sciences)	Schroder Ventures International Life Sciences Fund II Strategic Partners L.P	30,882
SV Life Sciences (formerly Schroder Ventures Life Sciences)	Schroder Ventures International Life Sciences Fund II Group Co-Investment Scheme	57,569
SV Life Sciences (formerly Schroder Ventures Life Sciences)	Schroder Ventures International Life Science Fund II LP 2	852,569
SV Life Sciences (formerly Schroder Ventures Life Sciences)	Schroder Ventures International Life Sciences Fund II LP1	2,001,830
SV Life Sciences (formerly Schroder Ventures Life Sciences)	Schroder Ventures International Life Sciences Fund II LP3	227,205
SV Life Sciences (formerly Schroder Ventures Life Sciences)	SV (Nominees) Limited	246,563

### Category Details

- Infections ( AIDS/HIV )
- Infections ( Bacterial Infections )
- Infections ( Hepatitis B )
- Infections ( Hepatitis C )

**Press release** On November 17, 2005, March 22, 2006 and May 12, 2006, the Registrant sold an aggregate of 23,425,462 shares of series C-2 convertible preferred stock to a group of 35 investors at a price per share of \$1.50. Upon the closing of this offering, these shares, together with the shares of series C-2 convertible preferred stock to be issued in satisfaction of accumulated dividends on the series C-2 convertible preferred stock (assuming for this purpose that the closing of the offering occurs on June 30, 2006), will automatically convert into 24,136,918 shares of common stock. The investors consisted of SGC Partners I LLC, Stelios Papadopoulos, Bear Stearns Health Innoventures, L.P., Bear Stearns Health Innoventures Offshore, L.P., BSHI Members, L.L.C., Bear Stearns Health

Innoventures Employee Fund, L.P., BX, L.P., Schroder Ventures International Life Sciences Fund II LP1, Schroder Ventures International Life Sciences Fund II LP2, Schroder Ventures International Life Sciences Fund II LP3, Schroder Ventures International Life Sciences Fund II Strategic Partners L.P., Schroder Ventures International Life Sciences Fund II Group Co-Investment Scheme, SV (Nominees) Limited as nominee for Schroder Ventures Investments Limited, Connecticut Innovations, Incorporated, Advent Partners HLS II Limited Partnership, Advent Partners Limited Partnership, Advent Healthcare and Life Sciences II Limited Partnership, Advent Healthcare and Life Sciences II Beteiligung GMBH & Co. KG, Atlas Venture Entrepreneurs' Fund V, L.P., Atlas Venture Fund V, L.P., Atlas Venture Parallel Fund V-A, C.V., Atlas Venture Parallel Fund V-B, C.V., Scheer Investment Holdings III, L.L.C., Barbara Piette, PGE Investments 2002, LLC, KBL Healthcare, L.P., KBL Partnership, L.P., Gilead Sciences, Inc., International Biotechnology Private Ltd., Pound Capital Corporation, Capital Ventures International, Christopher White, Peter Reikes, David Malcolm and Kim Fennebresque.

Source: [http://www.sec.gov/Archives/edgar/data/1070336/000119312506114379/ds1a.htm#toc85636\\_12](http://www.sec.gov/Archives/edgar/data/1070336/000119312506114379/ds1a.htm#toc85636_12)